Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.

Pioneer and leader in sublingual desensitization treatments, Stallergenes devotes more than 15% of its sales to Research and Development and is fully involved in the development of a new therapeutic class, the sublingual desensitization tablets.

Headquarted in France, Stallergenes markets its products through its subsidiaries or joint-ventures in Europe and through distribution agreements in other countries. In 2007, Stallergenes reached a turnover of 147.1 million euros, mainly achieved in the European markets.

Stock Market information

Eurolist Paris Compartment B
Indices: SBF 120, CAC Mid&Small 190 Index, CAC Small 90
ISIN code: FR 0000065674
FR 0010152447 (without coupon attached)
Reuters code: GEN.PA
Bloomberg code: GENP FP